{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:15:25Z","timestamp":1758046525150,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.pharma.2022.11.001","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T22:04:45Z","timestamp":1668204285000},"page":"529-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u00c9valuation de l\u2019impact budg\u00e9taire de l\u2019introduction d\u2019un traitement par \u00e9micizumab chez des patients atteints d\u2019h\u00e9mophilie A s\u00e9v\u00e8re cong\u00e9nitale sans inhibiteur"],"prefix":"10.1016","volume":"81","author":[{"given":"G.","family":"Oka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pieragostini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Roussel-Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Paubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Degrassat-Theas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2022.11.001_bib0180","unstructured":"L\u2019h\u00e9mophilie [Internet]. MHEMO. Disponible sur: https:\/\/mhemo.fr\/les-pathologies\/lhemophilie\/."},{"key":"10.1016\/j.pharma.2022.11.001_bib0185","unstructured":"L\u2019h\u00e9mophilie [Internet]. Orphanet. 2006. Disponible sur: https:\/\/www.orpha.net\/data\/patho\/Pub\/fr\/Hemophilie-FRfrPub646.pdf."},{"key":"10.1016\/j.pharma.2022.11.001_bib0190","unstructured":"Centre de R\u00e9f\u00e9rence H\u00e9mophilie et autres d\u00e9ficits constitutionnels en prot\u00e9ines de la coagulation. Protocole national de diagnostic et de soins (PNDS) h\u00e9mophilie [Internet]. 2019. Disponible sur: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2019-10\/pnds_hemophilie_argumentaire_10.10.19.pdf."},{"key":"10.1016\/j.pharma.2022.11.001_bib0195","unstructured":"R\u00e9seau FranceCoag. Statistiques nationales [Internet]. 2022. Disponible sur: https:\/\/www.francecoag.org\/SiteWebPublic\/public\/stats\/stats_page.jsp?stat2=on."},{"key":"10.1016\/j.pharma.2022.11.001_bib0200","unstructured":"European Medicines Agency. Hemlibra epar public assessment report [Internet]. EMA. 2018. Disponible sur: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/hemlibra-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.pharma.2022.11.001_bib0205","unstructured":"European Medicines Agency. Hemlibra epar public assessment report variation [Internet]. EMA. 2019. Disponible sur: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/hemlibra-h-c-4406-ii-0002-epar-assessment-report-variation_en.pdf."},{"key":"10.1016\/j.pharma.2022.11.001_bib0210","unstructured":"Roche. R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit - emicizumab (Hemlibra) [Internet]. 2022. Disponible sur: https:\/\/www.roche.fr\/content\/dam\/rochexx\/roche-fr\/roche_france\/fr_FR\/doc\/Produits\/Hemlibra\/Hemlibra-solution-injectable-common-SmPC-20220421.pdf."},{"key":"10.1016\/j.pharma.2022.11.001_bib0215","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Arr\u00eat\u00e9 du 11\u00a0mars 2020\u00a0modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques agr\u00e9\u00e9es \u00e0 l\u2019usage des collectivit\u00e9s et divers services publics. Journal Officiel, n\u00b0 0067\u00a0mars, 2020."},{"key":"10.1016\/j.pharma.2022.11.001_bib0220","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Arr\u00eat\u00e9 du 21\u00a0mai 2021\u00a0modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables aux assur\u00e9s sociaux. Journal Officiel, n\u00b00120\u00a0mai, 2021."},{"key":"10.1016\/j.pharma.2022.11.001_bib0225","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Commission de la Transparence - Avis 11\u00a0juillet 2018 - emicizumab [Internet]. HAS sant\u00e9. 2018. Disponible sur: https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-16921_HEMLIBRA_PIC_Ins_Avis2_CT16921.pdf."},{"key":"10.1016\/j.pharma.2022.11.001_bib0230","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Commission de la Transparence - Avis 2\u00a0octobre 2019 - emicizumab [Internet]. HAS sant\u00e9. 2019. Disponible sur: https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-17765_HEMLIBRA_PIC_EI_Avis2_CT17765_EPI653.pdf."},{"key":"10.1016\/j.pharma.2022.11.001_bib0235","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Arr\u00eat\u00e9 du 31\u00a0janvier 2019\u00a0modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques prises en charge en sus des prestations d\u2019hospitalisation mentionn\u00e9e \u00e0 l\u2019article L. 162-22-7\u00a0du code de la s\u00e9curit\u00e9 sociale. Journal Officiel, n\u00b00031\u00a0f\u00e9vr, 2019."},{"key":"10.1016\/j.pharma.2022.11.001_bib0240","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Arr\u00eat\u00e9 du 16\u00a0mars 2020\u00a0modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques prises en charge en sus des prestations d\u2019hospitalisation mentionn\u00e9e \u00e0 l\u2019article L. 162-22-7\u00a0du code de la s\u00e9curit\u00e9 sociale. Journal Officiel, n\u00b00067\u00a0mars, 2020."},{"key":"10.1016\/j.pharma.2022.11.001_bib0245","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Avis relatif aux prix de sp\u00e9cialit\u00e9s pharmaceutiques publi\u00e9s en application des articles L. 162-16-5\u00a0et L. 162-16-6\u00a0du code de la s\u00e9curit\u00e9 sociale. Journal Officiel, n\u00b00031\u00a0f\u00e9vr, 2019."},{"key":"10.1016\/j.pharma.2022.11.001_bib0250","doi-asserted-by":"crossref","DOI":"10.1111\/hae.14129","article-title":"Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France","volume":"27","author":"Polack","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.pharma.2022.11.001_bib0255","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-0039-3401822","article-title":"Cost-effectiveness and budget impact of Emicizumab Prophylaxis in haemophilia A patients with inhibitors","volume":"120","author":"Cortesi","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharma.2022.11.001_bib0260","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/13696998.2017.1405816","article-title":"Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden","volume":"21","author":"Henry","year":"2018","journal-title":"J Med Econ"},{"key":"10.1016\/j.pharma.2022.11.001_bib0265","unstructured":"Minist\u00e8re des affaires sociales et de la sant\u00e9. Avis relatif aux prix de sp\u00e9cialit\u00e9s pharmaceutiques publi\u00e9s en application des articles L. 162-16-5\u00a0et L. 162-16-6\u00a0du code de la s\u00e9curit\u00e9 sociale. Journal Officiel, n\u00b00076\u00a0mars, 2017."},{"key":"10.1016\/j.pharma.2022.11.001_bib0270","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of Emicizumab in persons with hemophilia A with factor VIII Inhibitors: HAVEN 1\u00a0Study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharma.2022.11.001_bib0275","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab Prophylaxis in patients who have Hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2022.11.001_bib0280","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4\u00a0weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3\u00a0study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.pharma.2022.11.001_bib0285","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/bjh.13365","article-title":"The current status of prophylactic replacement therapy in children and adults with haemophilia","volume":"169","author":"Ljung","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharma.2022.11.001_bib0290","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/trf.13016","article-title":"EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France","volume":"55","author":"Polack","year":"2015","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.pharma.2022.11.001_bib0295","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13023-017-0660-y","article-title":"The cost of severe haemophilia in Europe: the CHESS study","volume":"12","author":"O\u2019Hara","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.pharma.2022.11.001_bib0300","unstructured":"Minist\u00e8re de la sant\u00e9 et des sports. Arr\u00eat\u00e9 du 27\u00a0avril 2009\u00a0fixant la marge applicable aux m\u00e9dicaments inscrits sur la liste pr\u00e9vue \u00e0 l\u2019article L.5126-4\u00a0du code de la sant\u00e9 publique lorsqu\u2019ils sont vendus au public par les pharmacies \u00e0 usage int\u00e9rieur. Journal Officiel, n\u00b00100\u00a0avr, 2009."},{"key":"10.1016\/j.pharma.2022.11.001_bib0305","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Choix m\u00e9thodologiques pour l\u2019\u00e9valuation \u00e9conomique \u00e0 la HAS.2020."},{"key":"10.1016\/j.pharma.2022.11.001_bib0310","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Choix m\u00e9thodologiques pour l\u2019analyse de l\u2019impact budg\u00e9taire \u00e0 la HAS. 2016."},{"key":"10.1016\/j.pharma.2022.11.001_bib0315","first-page":"s126","article-title":"Economic costs of hemophilia and the impact of prophylactic treatment on patient management","volume":"22","author":"Chen","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.pharma.2022.11.001_bib0320","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/hae.14347","article-title":"Real-world cost estimates of initiating emicizumab in US patients with haemophilia A","volume":"27","author":"Samelson-Jones","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.pharma.2022.11.001_bib0325","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Hemophilia A with Inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2022.11.001_bib0330","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3\u00a0study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2022.11.001_bib0335","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2022.11.001_bib0340","unstructured":"Synth\u00e8ses nationales annuelles | Stats ATIH [Internet]. ScanScant\u00e9. Disponible sur: https:\/\/www.scansante.fr\/applications\/synthese-dmi-mo-sus."},{"key":"10.1016\/j.pharma.2022.11.001_bib0345","unstructured":"Nos Analyses [Internet]. GERS. Disponible sur: https:\/\/www.gie-gers.fr\/nos-analyses\/."},{"key":"10.1016\/j.pharma.2022.11.001_bib0175","unstructured":"Minist\u00e8re des solidarit\u00e9s et de la sant\u00e9. Avis relatif aux prix de sp\u00e9cialit\u00e9s pharmaceutiques. Journal Officiel, n\u00b00120\u00a0mars, 2021."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922001444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:37:33Z","timestamp":1757720253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450922001444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003450922001444"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9valuation de l\u2019impact budg\u00e9taire de l\u2019introduction d\u2019un traitement par \u00e9micizumab chez des patients atteints d\u2019h\u00e9mophilie A s\u00e9v\u00e8re cong\u00e9nitale sans inhibiteur","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2022.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}